EGFR and non-small cell lung carcinoma: Various reported have shown that the MEK pathway is activated according to anti-epidermal growth factor receptor treatment resistance in NSCLC, and inhibition of the MEK pathway attenuated PD-L1 up-regulation [13, 19].